Histone Deacetylase Inhibitors and Anaplastic Thyroid Carcinoma.

Eleftherios Spartalis, Dimitrios I Athanasiadis, Dimosthenis Chrysikos, Michael Spartalis, Georgios Boutzios, Dimitrios Schizas, Nikolaos Garmpis, Christos Damaskos, Stavroula A Paschou, Argyrios Ioannidis, Gerasimos Tsourouflis, Dimitrios Dimitroulis, Nikolaos I Nikiteas

Journal: Anticancer research 2019;39(3):1119-1127

PMID: 30842140

Full Text on HighWire View on PubMed

Abstract

BACKGROUND/AIM

Anaplastic thyroid cancer (ATC) is one of the most aggressive human malignancies, remaining generally incurable. Histone deacetylase (HDAC) seems to play a role in regulating transcription of genes involved in ATC, making HDAC inhibitors (HDACI) promising anticancer drugs for ATC. The purpose of this review was to evaluate the role of HDACIs in ATC treatment and describe the latest trends of current research on this field.

MATERIALS AND METHODS

This literature review was performed using the MEDLINE database. The keywords/phrases were; thyroid cancer, anaplastic, HDAC, histone, deacetylase*, HDACI.

RESULTS

Compounds, such as SuberoylAnilide Hydroxamic Acid, valproic acid, sodium butyrate, butyrate, phenylbutyrate, trichostatin A, AB1-13, panobinostat or LBH589, belinostat, MS-275, depsipeptide, CUDC101, CUDC907, N-Hydroxy-7-(2-naphthylthio)-Hepanomide (HNHA), and PXD101 have shown promising antitumor effects against ATC.

CONCLUSION

HDACIs represent a promising therapy for ATC management, both as monotherapy and in combination with other anticancer drugs.

Address: Laboratory of Experimental Surgery and Surgical Research N.S. Christeas, Medical School, National and Kapodistrian University of Athens, Athens, Greece [email protected].; 1st Department of Surgery, "Papageorgiou" General Hospital, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.; University Department of Surgery, General and Oncologic Hospital of Kifissia 'Agii Anargiri', Athens, Greece.; Laboratory of Experimental Surgery and Surgical Research N.S. Christeas, Medical School, National and Kapodistrian University of Athens, Athens, Greece.; Endocrine Unit, Department of Pathophysiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.; 1st Department of Surgery, Medical School, National and Kapodistrian University of Athens, Athens, Greece.; 2nd Department of Propaedeutic Surgery, Medical School, National and Kapodistrian University of Athens Athens, Greece.; Laboratory of Experimental Surgery and Surgical Research N.S. Christeas, Medical School, National and Kapodistrian University of Athens, Athens, Greece.; 2nd Department of Propaedeutic Surgery, Medical School, National and Kapodistrian University of Athens Athens, Greece.

DOI: 10.21873/anticanres.13220